<PAGE>
                 U. S. Securities and Exchange Commission
                         Washington, D. C.  20549


                                FORM 10-QSB


[X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the quarterly period ended June 30, 1999

[ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the transition period from                to
                                    --------------    ---------------


                       Commission File No. 0-24480


                           SANGUINE CORPORATION
              (Name of Small Business Issuer in its Charter)


           NEVADA                                        95-4347608
           ------                                        ----------
   (State or Other Jurisdiction of                 (I.R.S. Employer I.D. No.)
    incorporation or organization)

                        101 East Green Street, #11
                        Pasadena, California  91105
                        ---------------------------
                 (Address of Principal Executive Offices)

                Issuer's Telephone Number:  (626) 405-0079


Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.

(1)  Yes  X     No                 (2)  Yes  X    No
         ---     ---                        ---     ---

<PAGE>
             APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                PROCEEDINGS DURING THE PRECEDING FIVE YEARS

                              Not applicable.


                   APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the Registrant's classes
of common stock, as of the latest practicable date:

                               June 30, 1999

                                23,062,994
                                ----------


                      PART I - FINANCIAL INFORMATION


Item 1.   Financial Statements.

          The Financial Statements of the Registrant required to be filed with
this 10-QSB Quarterly Report were prepared by management, and commence on the
following page, together with Related Notes.  In the opinion of management,
the Financial Statements fairly present the financial condition of the
Registrant.
<PAGE>
                           Sanguine Corporation
                       (A Development Stage Company)

                           Financial Statements

                               June 30, 1999
<PAGE>
<TABLE>
                           SANGUINE CORPORATION
                       (A Development Stage Company)
                               Balance Sheet
                June 30, 1999 Unaudited & December 31, 1998
<CAPTION>
                                                     June    December
                                                   30, 1999  31, 1998
      Assets
<S>                                               <C>        <C>
Current Assets
  Cash                                            $     681  $     499

Property & Equipment
  Furniture                                             -0-         84

      Total Assets                                 $    681  $     583

     Liabilities & Stockholders  Equity

Current Liabilities
  Accounts Payable                                 $ 47,192  $  14,154
  Accrued Salaries                                  476,000    428,000
  Accrued Interest Payable                           36,150     33,420
  Notes Payable                                     149,546    135,450

      Total Current Liabilities                     708,888    611,024

Stockholders  Equity
  Common Stock, Authorized:
   100,000,000 Shares at $0.001 Par Value:
   23,062,994 & 23,010,217 Shares Issued
   & Outstanding Respectively                        23,072     23,010
  Paid In Capital                                   867,534    858,096
  Retained Earnings Deficit                      (1,598,813)(1,491,547)

      Total Stockholders  Equity                   (708,207)  (610,441)

      Total Liabilities &
      Stockholders  Equity                         $    681   $    583
</TABLE>
<TABLE>
                           SANGUINE CORPORATION
                       (A Development Stage Company)
                    Statements of Operations Unaudited
               For the Period April 1, 1999 to June 30, 1999
               and the Period April 1, 1998 to June 30, 1998
              and the Period January 1, 1999 to June 30, 1999
              and the Period January 1, 1998 to June 30, 1998
<CAPTION>
                                  April     April   January   January
                                1, 1999   1, 1998   1, 1999   1, 1998
                                to June   to June   to June   to June
                               30, 1999  30, 1998  30, 1999  30, 1998
<S>                           <C>       <C>       <C>       <C>
Revenues                       $    -0-  $    -0-  $    -0-  $    -0-

     Total Revenues                 -0-       -0-       -0-       -0-

Expenses
  Promotion                       4,226     3,710     4,226     3,710
  Depreciation                      -0-       230        84       460
  Research & Development         19,500    79,500    39,000    99,000
  Office Expense                  3,843     1,961     5,816     4,885
  Auto Expense                    4,660       180     4,930       450
  Salaries                        4,500     4,500     9,000     9,000
  Legal & Professional Fees       2,964    22,845    10,831    23,491
  Rent                            1,390     4,799     6,189     9,598
  Interest Expense                5,074     4,145     9,956     7,901
  Stock Transfer                    -0-       472       300       496
  Tax & License                   1,600     1,097     1,600     1,097
  Travel                          2,710       -0-     2,710       -0-
  Insurance                      12,624       -0-    12,624       -0-

     Total Expenses              63,091   123,439   107,266   160,088

     Loss for Period           ($63,091)($123,439)($107,266)($160,088)

     Profit (Loss) Per Share   ($   .00) ($   .01) ($   .00) ($   .01)

   Weighted Average Shares
   Outstanding               23,062,994 21,134,970 23,062,994 21,134,970
</TABLE>
<TABLE>
                           SANGUINE CORPORATION
                       (A Development Stage Company)
                    Statements of Cash Flows Unaudited
           For the Periods January 1, 1999 to June 30, 1999 and
                     January 1, 1998 to June 30, 1998
<CAPTION>
                                                     June      June
                                                   30, 1999  30, 1998
<S>                                                <C>       <C>
Cash Flows from Operating Activities
 Net (Loss)                                       ($107,266)($160,088)
 Adjustments to Reconcile Net Loss to Net
  Cash Used by Operations:
   Depreciation                                          84       460
 Changes in Operating Assets & Liabilities:
  (Decrease) Increase in Accounts Payable            33,038  (  4,480)
  Increase in Interest Payable                        2,730     2,730
  Increase in Accrued Salaries                       48,000    48,000

      Net Cash Flows from
      Operating Activities                         ( 23,414) (113,378)

Cash Flows from Investing Activities

      Net Cash Used by
      Investing Activities                              -0-       -0-

Cash Flows from Financing Activities
 Increase in Investor Deposit                           -0-    60,000
 Increase in Notes Payable                           14,096    16,000
 Sale of Common Stock                                 9,500    42,033

      Net Cash Flows Provided by
      Financing Activities                           23,596   118,033

      Increase (Decrease) in Cash                       182     4,655

      Cash at Beginning of Period                       499       263

      Cash at End of Period                        $    681  $  4,918

Disclosure for Cash Flows from:
 Interest                                          $  9,956  $  7,901
 Taxes                                                 -0-       -0-
</TABLE>
                           SANGUINE CORPORATION
                       Notes to Financial Statements

NOTE #1 - Statement Preparation

The Company has prepared the accompanying financial statements with interim
financial reporting requirements promulgated by the Securities & Exchange
Commission.  The information furnished reflects all adjustments which are, in
the opinion of management, necessary for a fair presentation of financial
position and results of operations.

The financial statements should be read in conjunction with the consolidated
financial statements and notes thereto included in the Company's 1998 10-K
report.

NOTE #2 - Current Events

The Company  issued 52,777 shares for working capital of $9,500 during the six
months ended June 30, 1999.

<PAGE>
Item 2.   Management's Discussion and Analysis or Plan of Operation.
--------------------------------------------------------------------

Plan of Operation.
------------------

          The Company has conducted all of its business operations through its
majority owned subsidiary, Sanguine Corporation, a California corporation
("Sanguine California").  Sanguine California is engaged in the development of
a synthetic red blood cell product called "PHER-O2."  The development of this
product presently comprises its sole business operations.  PHER-O2 is composed
of perfluoro-decalin molecules (i.e., synthetic red blood cells), purified
water and a proprietary, synthetic, fluorinated surfactant to hold the
emulsion together.  Perfluoro-decalin has great oxygen-carrying capacity, yet
it can be as much as 900 times smaller than a red blood cell.  Management
believes that PHER-O2 may carry three to four times the oxygen of human blood
per unit volume. This increased oxygen-carrying capacity may make PHER-O2
useful in the treatment of heart attacks, strokes, cancer and other diseases
for which increased oxygenation is beneficial.  Furthermore, the Company
believes that perfluoro-decalin may be effective as an imaging agent in X-ray
imaging, nuclear magnetic resonance (NMR) imaging and CAT scans, without side
effects. Management also believes that PHER-O2 has several other advantages
over human blood:  it can be sterilized to be free of disease; is believed to
have the quality of a universal match for all blood types; can be
mass-produced; and may be stored much longer than human blood.

          Battelle Memorial Institute, through its Battelle Columbus
Operations ("Battelle"), was retained to assist the Company in completing the
emulsion of perfluoro-decalin and the synthetic surfactants that make up
PHER-O2; it is anticipated that on completion of the compounding of PHER-O2,
Battelle will perform initial gross animal tests, which do not require
regulatory approval prior to commencement; however, the data gathered from any
such tests will be subject to regulatory review in the future.  The Company
anticipates that it will manufacture experimental doses of PHER-O2 required to
conduct gross animal testing.

          Battelle is not conducting any research and development activities
pending receipt of further funding from the Company. It is anticipated that
continued research and development of PHER-O2 will depend upon the Company's
ability to obtain substantial additional equity or debt funding, as to which
no assurance can be given.  See the captions "Business Development," "Future
Capital Requirements; Uncertainty of Future Funding" and "Patents, Trademarks,
Licenses, Franchises, Concessions, Royalty Agreements or Labor Contracts" of
the Company's Annual Report on Form 10-KSB for the calendar year ended
December 31, 1998, which has previously been filed with the Securities and
Exchange Commission.

          In its second phase of operations, management intends to continue
developing the perfluorocarbon compounds in PHER-O2 in order to optimize its
quality, and expects to begin animal safety and efficacy trials in accordance
with guidelines of the United States Food and Drug Administration ("FDA") and
comparable foreign regulatory requirements.

          In the final phase of the Company's proposed business operations, it
intends to complete its United States testing of PHER-O2, receive all
necessary FDA approvals and begin American and Canadian sales for cancer
treatment and angioplasty; and complete overseas testing, begin overseas sales
and begin the construction of manufacturing facilities.  Sanguine California
has previously licensed BioLogix Development Partners, an unaffiliated
California limited partnership, to manufacture and market PHER-O2 in Canada,
including any future Canadian patent rights, and the exclusive right to market
PHER-O2 in U.S. military pre-hospital markets.  In this final phase, the
Company also intends to continue trials to test PHER-O2  for other
applications, including transplant organ preservation and the treatment of
carbon monoxide poisoning, sickle cell anemia, heart attack and stroke.  The
Company will be required to conduct similar rigorous testing and clinical
trials of PHER-O2 for each desired application for which it is sought to be
used.

          PHER-O2 is still in the research and development stage.  It has not
been tested on animals or humans; nor has any application been submitted to
any federal, state or foreign agency to seek authority for such testing.  This
development process will be time consuming, costly, subject to extreme
governmental regulation and must prove that this product is safe and
efficacious for human use.  Until then, the Company will have no potential for
revenues from operations.  No assurance can be given that the Company will be
able to raise the capital it will need to develop PHER-O2, or that if
sufficient funds are raised, the Company will ever receive requisite federal,
state or foreign agency approval to manufacture or market this product.  See
the captions "Business Development," "Special Risk Factors," "Principal
Products or Services and their Markets," "Competition," "Patents, Trademarks,
Licenses, Franchises, Concessions, Royalty Agreements or Labor Contracts" and
"Governmental Approval of Principal Products or Services" of the Company's
Registration Statement on Form 10-SB-A1, which has previously been filed
with the Securities and Exchange Commission, and which is incorporated herein
by reference.

Results of Operations.
----------------------

          During the quarterly period ending June 30, 1999, the Company's
only business operations were those of Sanguine California.  During this
period, the Company received total revenues of $0 and sustained a net
loss of ($63,091).

Liquidity.
----------

          During the quarterly period ended June 30, 1999, the Company
had total expenses of $63,091, while receiving $0 in revenues.

Year 2000
---------

          The use of computer programs that rely on two-digit date codes to
perform computations or decision-making functions has become widespread.  Many
of these programs may fail as a result of their inability to properly
interpret date codes beginning on January 1, 2000.  For example, such programs
may interpret the year code "00" as the year 1900 rather than 2000.

          The Company has ceased its research and development activities
pending the receipt of the additional funding required by Battelle.  At
present, the Company's computer operations are limited to word processing,
which is not highly susceptible to Year 2000 issues.  However, the Company can
provide no assurance that the systems of other entities such as banks and
utilities will be modified on a timely basis, or that such an entity's failure
to properly modify its systems will not have an adverse effect on the Company.

                        PART II - OTHER INFORMATION

Item 1.   Legal Proceedings.
----------------------------

          There have been no material changes in the pending litigation with
H. J. Nicholas, Utah Third District Court Case No. 980901388, as described in
Part I, Item 3, of the Company's Annual Report on 10-KSB for the year ended
December 31, 1998, which was filed with the Securities and Exchange Commission
on April 15, 1999.  See the Exhibit Index, Item 6 of this Report.

Item 2.   Changes in Securities and Use of Proceeds.
---------------------------------------------------

          None; not applicable.

Item 3.   Defaults Upon Senior Securities.
------------------------------------------

          None; not applicable.

Item 4.   Submission of Matters to a Vote of Security Holders.
--------------------------------------------------------------

          None; not applicable.

Item 5.   Other Information.
----------------------------

          None; not applicable.

Item 6.   Exhibits and Reports on Form 8-K.
-------------------------------------------

          (a)  Exhibits.

               10-SB-A1 Registration Statement.*

               Form 10-KSB Annual Report for the
               Fiscal Year ended December 31, 1998.*

          (b)  Reports on Form 8-K.

               None.

               *  Incorporated herein by reference.

                               SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                      SANGUINE CORPORATION



Date: 8/13/99                        By:/s/Thomas C. Drees
     --------------                     -------------------------------------
                                        Thomas C. Drees, CEO, President and
                                        Chairman of the Board of Directors


Date: 8/13/99                        By:/s/Anthony G. Hargreaves
     --------------                     -------------------------------------
                                        Anthony G. Hargreaves
                                        Vice President, Secretary/Treasurer
                                        and Director


Date: 8/16/99                        By:/s/David E. Nelson
     --------------                     -------------------------------------
                                        David E. Nelson
                                        CFO and Director